Abstract
In a randomised prospective study 61 patients with lower urinary tract infection received either 200 mg norfloxacin (33 patients) or 480 mg cotrimoxazole (28 patients) twice daily for ten days. Pathogens includedEscherichia coli in 48 patients,Proteus mirabilis in ten patients, andEnterobacter cloacae, Klebsiella pneumoniae, Citrobacter freundii andStaphylococcus saprophyticus in one patient each. The MICs of norfloxacin and cotrimoxazole were ⩽ 0.03 mg/l and ⩽ 1 mg/l respectively. On the tenth day of treatment 94 % of the patients receiving norfloxacin and 89 % of the patients receiving cotrimoxazole were clinically cured, and the pathogens were eradicated in 94 % and 96 % of the patients respectively. At six week follow-up one patient given cotrimoxazole and two given norfloxacin had a reinfection. No side-effects or toxicity were observed with the exception of a diffuse rash in one patient receiving cotrimoxazole in whom treatment was discontinued. It is concluded that norfloxacin is safe and as effective as cotrimoxazole in the treatment of lower UTI and should have an important role to play whenever multiresistant organisms are implicated.
Similar content being viewed by others
References
Downs, J., Andriole, V. T., Ryan, J. L.: In vitro activity of MK-0366 against clinical urinary pathogens, including gentamicin-resistantPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1982, 21: 670–672.
Ito, A., Hirai, K., Inone, M., Koga, H., Suzue, S., Irijura, I., Misuhashi, S.: In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrobial Agents and Chemotherapy 1980, 17: 103–108.
King, A., Warren, C., Shannon, K., Phillips, I.: In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrobial Agents and Chemotherapy 1982, 21: 604–607.
Thomas, V., Shelokov, A., Forland, M.: Antibodycoated bacteria in the urine and site of urinary tract infection. New England Journal of Medicine 1974, 290: 588–590.
Washington, J. A., Sutter, V. L.: Dilution susceptibility test: agar and macro-broth dilution procedures. In: Lennette, E. H., Balows, A., Hausler, W. J., Truant, J. P. (ed.): Manual of clinical microbiology. American Society for Microbiology, Washington, D.C., 1980, p. 453–458.
Giamarellou, H., Jackson, G. G.: Antibacterial activity of cinoxacin in vitro. Antimicrobial Agents and Chemotherapy 1975: 688–692.
Boppana, V. K., Swanson, B. N.: Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrobial Agents and Chemotherapy 1982, 21: 808–810.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giamarellou, H., Tsagarakis, J., Petrikkos, G. et al. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur. J. Clin. Microbiol. 2, 266–269 (1983). https://doi.org/10.1007/BF02029530
Issue Date:
DOI: https://doi.org/10.1007/BF02029530